Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Creating evidence to tackle COVID-19

Our COVID-19 reading template is in use for two weeks, and its usage is multiplying. We are grateful for the close cooperation and feedback from existing and new mint Lesion™ users.

Our medical team went through all the available publications and created a reading template that can be used with ease by readers in your hospital or research center. As new papers and guidelines become available, we will update the reading template, retaining the structured data already collected.

mint Lesion™ extracts all primary data - including radiomics features - from images, and immediately links any measured value to its context and further related data of clinical significance. Together with clinical endpoints, the mineable data is ready for real-time analytics and AI.

Let mint Lesion™ assist you in generating the data and creating the evidence that will enable us to tackle COVID-19 jointly.

Request a demo

Related Resources

Related Resources

A doctor pushes a lying patient into the LDCT device

Early lung cancer detection through LDCT screening as a potential way to improve patient outcomes in Germany

The establishment of a nation-wide lung cancer screening program in Germany has been a subject of considerable interest and debate among healthcare…

A group of people standing together, looking up at the camera. The picture says: Together we're making an impact.

RACOON FHIR Workshop: Empowering Healthcare Research via Enhanced Interoperability

This week Brainlab hosted the RACOON FHIR Workshop with around 40 participants. The workshop was organized by Mint Medical and supported by Snke OS,…

A screenshot of a structured report from mint Lesion™

Tumor Growth Rate Modeling: A Novel Approach to Evaluating the Efficacy of Cancer Therapies

The 2020 review of Clinical Trial Evidence Supporting US Food and Drug Administrative Approval of Novel Cancer Therapies Between 2000 and 2016…